Perspective Therapeutics (CATX) vs CapsoVision (CV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CapsoVision (CV) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 38.9% versus a loss of 29.1%. CapsoVision is the larger company by market cap ($348.0 million vs $280.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | CV |
|---|---|---|
| Share price | $2.46 | $6.54 |
| Market cap | $280.81M | $348.00M |
| 1-day change | +4.24% | +0.62% |
| YTD return | -10.55% | -38.82% |
| 1-year return | -29.11% | +38.85% |
| 5-year return | -60.32% | — |
| EPS (TTM) | $-1.39 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $15.37 |
| 52-week low | $1.96 | $4.38 |
| Distance from 52-week high | -60.06% | -57.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +399.59% | +45.26% |
| Average volume | 1.68M | 158.95K |
| Shares outstanding | 114.15M | 53.21M |
| Employees | 163 | 99 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CV has outperformed CATX by 68.0 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Healthcare · Medical Devices · 163 employees
About CapsoVision
CV stock →CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Healthcare · Medical Devices · 99 employees
CATX vs CV FAQ
Which is bigger, Perspective Therapeutics or CapsoVision?
CapsoVision (CV) is larger, with a market capitalization of $348.00M compared with $280.81M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or CV?
CV returned +38.85% over the past 12 months, compared with -29.11% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and CapsoVision in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.